INmune Bio (INMB) Q4 2025 earnings review
Cost Cuts and PRV Reauthorization Buy Time for CORDStrom
INmune Bio ends 2025 transitioning into a late-stage company, aggressively cutting costs to extend its cash runway to Q1 2027. Net loss widened to $45.9M (vs $42.1M in FY24), but this was entirely driven by a $16.5M non-cash impairment charge taken earlier in the year on the XPro asset. Operationally, the company is demonstrating strict capital discipline: annual R&D expenses plummeted 38% YoY to $20.7M. The legislative reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) program through 2029 removes a massive cliff-edge risk, ensuring that a successful CORDStrom approval for RDEB will yield a highly monetizable asset. Meanwhile, management secured FDA alignment for a precision-medicine pathway for XPro, though funding that Phase 3 trial remains a glaring question mark.
🐂 Bull Case
The reauthorization of the PRV program to 2029 transforms CORDStrom from a niche rare-disease drug into a potential non-dilutive funding engine. A PRV can often be sold for $100M+, which would fundamentally change INmune's balance sheet.
Despite earlier clinical setbacks, the FDA agreed to a Phase 2b/3 adaptive trial design focusing purely on biomarker-enriched patients with neuroinflammation, providing a clear regulatory roadmap.
🐻 Bear Case
With only $24.8M in cash, INmune cannot independently fund the newly aligned Phase 2b/3 Alzheimer's trial. They remain entirely dependent on finding a strategic partner willing to underwrite the costs.
The dramatic drop in R&D spend and the lack of forward guidance on INKmune indicates the company is effectively putting all its near-term chips on the CORDStrom regulatory filings.
⚖️ Verdict: ⚪
Neutral. Management is executing well on what they can control—slashing cash burn, advancing CORDStrom manufacturing, and securing regulatory alignment. However, the company remains a binary regulatory play on CORDStrom, heavily reliant on external capital to advance its Alzheimer's asset.
Key Themes
Macro Tailwind: PRV Program Reauthorization
A critical legislative risk was removed with the reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) program through 2029. In previous quarters, management operated under the assumption that CORDStrom had to be approved by September 2026 to qualify. This extension significantly de-risks the commercial profile of CORDStrom, turning it into a dual-value proposition: a therapy for RDEB and a highly lucrative, monetizable voucher.
CORDStrom Manufacturing and Regulatory Readiness
The timeline for CORDStrom is Stable and accelerating toward execution. The company successfully completed three commercial pilot-scale manufacturing runs at its Stevenage facility, meeting all release criteria. This derisks the CMC (Chemistry, Manufacturing, and Controls) portion of their upcoming filings. A face-to-face meeting with the UK's MHRA is set for May, pacing toward a mid-summer MAA filing.
Innovation: XPro Precision Biomarker Trial Design
INmune secured FDA alignment for a highly innovative, adaptive Phase 2b/3 pathway for XPro. By utilizing a biomarker-enriched design targeting only patients with neuroinflammation, they are bridging early cognitive signals (EMACC at 9 months) to late-stage functional outcomes (CDR-SB at 18 months). The Phase 2b stage acts as a powered 'go/no-go' decision point before committing to the expensive Phase 3 portion.
XPro's Standalone Value Severely Damaged
While management paints a rosy picture of FDA alignment for XPro, the hard financial data contradicts the standalone strength of the asset. The company's $45.9M net loss in 2025 was heavily driven by a $16.5M impairment charge booked against acquired in-process R&D for XPro. This write-down followed the MINDFuL trial missing its broad-population primary endpoint earlier in the year, proving that the asset's path forward is narrower, riskier, and entirely dependent on retrospective subgroup analysis.
Capital Requirements for Phase 3 Unmet
Management explicitly states the Phase 2b/3 XPro program represents a 'compelling partnership opportunity.' This is coded language acknowledging they lack the balance sheet to run it themselves. With $24.8M in cash, their runway only extends through Q1 2027—enough to get CORDStrom filed, but not enough to initiate pivotal Alzheimer's trials without a dilutive raise or a strategic partner.
INKmune Effectively Shelved
Despite meeting the primary and two secondary endpoints in the CARE-PC trial for metastatic castration-resistant prostate cancer, the tone regarding INKmune has shifted to 'ongoing analysis to inform future development.' With R&D expenses cut by $12.5M YoY, it is clear INKmune is not receiving meaningful capital allocation at this time.
Other KPIs
Decelerating sharply. R&D spending dropped 38% from $33.2M in FY24. This reflects the conclusion of the XPro MINDFuL Phase 2 trial, the halting of further broad XPro enrollment, and a strategic shift toward capital preservation while preparing regulatory filings for CORDStrom.
Stabilizing. Up from $20.9M at the end of FY24, bolstered by $27.5M in net proceeds from equity sales throughout the year and a $3.6M Australian R&D rebate. Management has successfully stretched this cash to provide a runway through Q1 2027, covering all major CORDStrom regulatory filing milestones.
Guidance
Stable. The company remains on track with its prior guidance to file its first Marketing Authorization Application in the UK by mid-summer, following a scheduled face-to-face meeting with the MHRA in mid-May.
Stable. Following the UK filing, the company plans to submit its Biologics License Application to the FDA in the fourth quarter of 2026.
Accelerating/Improving. Previous guidance throughout 2025 suggested cash would run out by Q3/Q4 2026. The combination of equity sales and aggressive R&D cost-cutting has extended the runway slightly into early 2027.
Key Questions
XPro Partnership Timeline
Now that you have FDA alignment on the adaptive Phase 2b/3 design for XPro, what is the realistic timeline for securing a strategic partner? Will you initiate the Phase 2b portion independently, or wait for a partner to fund the first patient dosed?
CORDStrom Commercialization Strategy
With commercial pilot-scale manufacturing runs complete and filings imminent, how are you planning for the commercial launch of CORDStrom? Are you building an internal sales force for the rare disease market, or seeking a commercial partner?
PRV Monetization
Given the extension of the PRV program to 2029, if CORDStrom is approved, do you plan to monetize the voucher immediately to non-dilutively fund the XPro pipeline, or retain it for internal use?